Summary Factors associated with the failure of intravenous infusions due to phlebitis and extravasation were studied with 218 infusions delivering cytotoxic drugs. The survival rate of these infusions was not significantly different from that of 56 non-cytotoxic infusions in oncology patients. Although survival analysis indicated that cisplatin was associated with longer survival, this was probably an artifact caused by this drug usually being preceded by 24 h prehydration. Multivariate analysis indicated that etoposide was the only drug associated with decreased infusion survival and that bleomycin, cyclophosphamide, doxorubicin, ifosphamide, methotrexate, treosulphan and 5-fluorouracil had no significant effects. Also age of patient, infusion site and flow rate had no effects but survival was shorter in women. Follow-up When an infusion site could be located precisely at a subsequent visit (from notes and the patients memory), patency of the vein proximal to the infusion site was determined by inspection and palpation.
Cytotoxic chemotherapy is frequently given by intravenous infusions. There is a common belief that cytotoxic drugs are highly irritant to veins and frequently cause phlebitis which results in the loss of many superficial veins. Consequently difficult venous access during later stages of treatment is experienced by some patients. Band and Maki (1980) (e.g Rudolph & Larson, 1987; Cohen, 1979; Lynch et al., 1979; Upton et al., 1979) but there are a few reports of phlebitis following bolus injections of concentrated solutions of cytotoxic drugs (Baglin & Boughton, 1986 ) and isolated comments in several papers to the effect that particular drugs are 'irritant' or cause phlebitis, extravasation or vein loss (e.g Long et al., 1987) . The only survey done to identify which cytotoxic drugs are thrombophlebitic (Henney et al., 1977) (Peto et al., 1977 When an infusion site could be located precisely at a subsequent visit (from notes and the patients memory), patency of the vein proximal to the infusion site was determined by inspection and palpation.
Results
Of 284 infusion sites studied, 78 (27.4%) failed with 32 extravasating, 41 becoming phlebitic and five extravasating with obvious phlebitic signs. Of the failed infusions, 46 (13 for extravasation and 32 for phlebitis) required resiting for treatment (usually less than 72 h) to continue. In addition, four, three, one and one infusions were resited because of 'blockage', dislodgement, clotting and leakage respectively but these were not classed as failed.
Statistics for oncology patients such as age, sex, cannula site and average fluid rate are shown in Table I . None of these factors was significant by univariate analysis.
Cytotoxic drugs were infused at 228 sites while the 56 other sites received only crystaloid fluids and sometimes antibiotics. There was no significant difference between cytotoxic and non-cytotoxic infusions (RRFs 1.02 and 0.99 respectively, X2=0.01) (Figure 1 ).
The most common drug given was cisplatin with bleomycin, etoposide, methotrexate, treosulphan and 5-fluorouracil (5-FU) also being used frequently. Other drugs (mitozan, JM8 and vinblastine) were used only occasionally (three, two and one times respectively). Univariate analyses of survival of infusions with individual drugs (Table II) showed that only cisplatin was associated with a statistically significant difference (this was longer survival). Hecker, 1989) . This irritation probably causes venoconstriction which, prior to the development of clinical phlebitis, slows and makes the drip rate irregular . Alternatively venoconstriction may stop flow through the vein, leading to leakage (extravasation) through the hole made where the cannula was inserted into the vein . The distinction between phlebitis and extravasation at times is unclear as swelling at the time of cannula removal indicates extravasation but this disappears after a few hours making the phlebitic signs of tenderness and vein cording more apparent. In a separate survey comparing extravasation with phlebitis, there was no significant difference in the life tables for failure due to phlebitis and due to extravasation (Hecker, 1989 Once a vein has been exposed to a drug, the risk of failure resulting from any local irritation from the drug should be increased for many hours and so potentially could be detected with survival analysis.
However, two drugs, bleomycin and cisplatin, which were administered by short infusions were usually not given until several hours after infusions had commenced. The pre-hydration period for cisplatin was typcially 24 h and infusions that failed before it had been given were not classed as cisplatin infusions as the drug could not have affected the vein. This resulted in decreasing the RRF for cisplatin (equivalent to shifting its survival curve to the right). There was a similar but smaller effect for bleomycin as pre-hydration was normally only for 6 h. There is no simple solution to this problem (Anderson et al., 1980) but, as it is improbable that cisplatin would decrease infusion failure, then the likelihood is that it had no effect. Henney et al. (1977) reported briefly that 27 of 82 agents investigated by the Cancer Therapy Evaluation Program of the National Cancer Institute were implicated with frequent incidences of thrombophlebitis. The only relevant detail given was that no drug was given by 'prolonged intravenous infusion'. Of the drugs studied here, only doxorubicin was in their group classed as 'frequent incidence' while bleomycin, vincristine and 5-FU were in the 'frequent' group. The failure rate ratio for doxorubicin was high (Table II) and it might be that the number of infusions with this drug was too small for more than a large significant difference to be detected. Alternatively it may be that it does not irritate the vein during transient passage along it but only causes problems only after extravasating.
Almost one-quarter of these cytoxic infusions failed. This may have been a slight under-estimation as five patients later reported that phlebitic-like signs developed after they had left hospital. To put this 23% failure rate in perspective, the survival curve for cytotoxic infusions was similar to that for non-cytoxic infusions given to oncology patients and significantly better (x2 = 7.69, P> 0.01; failure ratio = 0.66) than for 357 infusions in non-oncology patients in the hospital (Hecker, in preparation) . Band and Maki (1980) reported a phlebitis rate of 36.1% for oncology patients.
These data show that it is unlikely that the drugs given frequently, bleomycin, cisplatin and methotrexate, are irritant. Fewer infusions involved the other drugs and so only extreme irritancy would be detecting.
The lack of evidence for irritancy for drugs other than etoposide suggests that failure was caused by other factors which were common to both the cytoxic and non-cytoxic infusions. Similar surveys of intravenous antibiotics and other drugs have identified relatively few drugs that increase infusion failure (Hecker, 1989; Hecker et al., unpublished data) . However, acidity of the dextrose and saline crystaloid solutions (typically pH 4.5 and 5.5 respectively (Lebowitz et al., 1971; Mostert, 1971; Tse, 1971) ) is probably important. These solutions are given in large volumes, are mildly irritant to veins, and have often been implicated in the failure of intravenous infusions as neutralisation decreases the incidence of failure (Eremin & Marshall, 1977; Flores-Vega et al., 1970; Fonkalsrud et al., 1968) .
The multivariate analysis suggested that failure was significantly more rapid in women. I have done three surveys of non-oncology patients using similar methods and sex was identified as one of the few significant factors (failure more rapid in women) in two (unpublished) but not in the third (Hecker, 1989) . The reason for a possible sex effect is unknown.
Problems with venous access were apparent in many of these patients and three required either use of foot veins or a central venous line for therapy to continue. Cannulation of hand and arm veins was often difficult in many other patients and it appeared that previous therapy had resulted in the loss of many superficial veins. Follow-up was possible only for a proportion of patients but it showed that the occurrence of phlebitis and/or extravasation usually resulted in vein loss, sometimes with the formation of a hard palpable cord.
Observations have led me to the conclusion that progressive vein loss due to repeated intravenous therapy is also a problem in other than oncology patients. However, it has received no attention in the medical literature. Techniques which reduce the incidence of infusion failure, such as local transcutaneous glyceryl trinitrate (Wright et al., 1985; Khawaja et al., 1988) or the addition of small amounts of heparin to solutions (Tanner et al., 1980; DeCock et al., 1984; Alpan et al., 1984) could be considered to conserve veins of oncology patients who are likely to require repeated intravenous therapy.
There is no recognised method for identifying drugs which have deleterious effects on veins and it is difficult to find the origins of statements in promotional and other literature that particular drugs 'may cause phlebitis'. I suggest that new intravenous chemotherapeutic drugs should be tested by methods similar to these (i.e. compared with similar infusions without the drug) to identify any that are irritant.
